The TARGIT-A randomized trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival

For assessing the efficacy of any cancer therapeutic approach, patients and clinicians want to know the chance of being free of disease as well as the likelihood of achieving long-term survival. Single-dose targeted intraoperative radiation therapy (TARGIT-IORT) during lumpectomy for patients with early breast cancer can avoid the inconvenience and toxicity of whole breast radiation therapy (external beam radiation therapy [EBRT]) and results in reduced pain, a better quality of life, a cosmetically superior outcome, and requires less traveling by the patient